Case of HIV Remission in South African Child | |
 | After very early antiretroviral therapy during infancy, an HIV-positive child has been able to suppress the virus without any meds for eight and a half years. |
This Week in HIV Research: Injectable PrEP Shows Promise in New Study | |
A study finds that injectable cabotegravir, an investigational integrase inhibitor, is well tolerated and shows promise as pre-exposure prophylaxis. |  |
The Future of 2-Drug Regimens for People With HIV | |
 | Reducing the number of drugs in a treatment regimen lowers long-term drug exposure and potential drug toxicity or drug interactions. |
What's New or Notable in HIV Treatment and Prevention Adherence? | |
 | Care providers share their thoughts on the latest in HIV treatment and prevention adherence. |
An ongoing series to help providers set the foundations of a patient's care.
What's New or Notable in HIV Treatment and Prevention Adherence?
Progress and Gaps in Scaling Up Universal HIV Treatment in Africa
Starting HIV Treatment Soon After Diagnosis Trims Time to Viral Suppression
What's the Next Game-Changer in HIV Treatment?
The field of hepatitis C disease management is in the midst of dramatic change. This series provides overviews, research updates, and more.
Hepatitis C: How Is It Transmitted and Who Should Be Tested?
Addressing Hepatitis C Treatment Barriers Among HCV/HIV-Coinfected Patients
What Are the Hepatitis C Genotypes?
Hepatitis C Resources, Services and Information
Views From the Front Lines: Getting to Undetectable
MK-8591: Further Compelling Early Results for Both Treatment and Prevention
Cancer Causes 10% of Deaths Among People With HIV in U.S., Canada
Comment on CDC Correcting Misleading HIV Conception Guidance, Responding to Community Pressure
PleasePrEPMe.org and Project Inform Launch New PrEP Navigation Manual in California
HIV Tied to Greater Erectile Dysfunction Among Men Over 45
CDC Corrects Misleading HIV Conception Guidance, Responding to Community Pressure
Which Hepatitis C Treatment to Start in 2017
Understanding Exactly How the "Berlin Patient" Was Cured
What Factors Increase the Effectiveness of Behavioral Interventions for HIV Prevention?
Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study
HIV Pipeline Drugs: IAS 2017 Update
This Week in HIV Research: A New Glimpse Into HAND
Mosaic HIV Vaccine Candidate Shows Promise in Early-Stage Trial
Notice to readers: TheBodyPRO.com's privacy policy was updated on Sept. 20, 2016.
© 2017 Remedy Health Media, LLC. All Rights Reserved
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
